Campath may be approved by the Food and Drug Administration (FDA) to treat leukemia, but that doesn’t mean multiple sclerosis (MS) patients should take the drug.
The FDA issued a public health advisory stating the death of one patient in a clinical study that examined the use of Campath to treat MS. Three other patients developed severe idiopathic thrombocytopenic purpura, a blood disorder. Currently, the drug is not used to treat MS, but clinical tests were being done to determine its success in treating the disease. MS is a disorder that affects the brain and spinal cord.
The MS study has been suspended, and a black-box warning has been put on Campath warning of the possibility of patients developing serious blood problems.
For more information about recalled drugs, visit our Dangerous Drug and Recall Legal Center.